Nucart - OA

Quick links to important sections

Nucart - OA

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nucart - OA

Property Description
Active ingredient Glucosamine Sulphate
Form Oral Tablets or Capsules
Pharmacological class Chondroprotective Agent / Amino Sugar Supplement
Common purpose Structural support for joint cartilage
Origin Semi-synthetic (derived from chitin)

The formulation known as Nucart-OA is a preparation containing the active ingredient Glucosamine Sulphate, which is recognized within pharmacology as a Chondroprotective Agent. This preparation is supplied for oral administration as a single active ingredient product in the form of tablets or capsules. The product is defined by its role as an external source of a compound naturally found in the body's connective tissues.

Composition: Glucosamine Sulphate and its Origin

The active substance, Glucosamine Sulphate, is an essential amino sugar necessary for the production of core cartilage components. Glucosamine itself is a naturally occurring substance; however, the ingredient utilized in many preparations is generally semi-synthetic, meaning it is derived from the chitin sourced from marine exoskeletons. The specific sulphate form is considered structurally important because the sulphate moiety is critical for the biochemical synthesis of crucial structural elements in cartilage, such as glycosaminoglycans and Type II collagen.

General Purpose and Structural Benefit

The primary purpose of consuming this preparation is to provide the body with the necessary building blocks to support and maintain the health of articular cartilage. Glucosamine Sulphate is utilized to address the structural components of the joint, rather than delivering immediate symptomatic relief. This ingredient functions as a key precursor that helps support the body’s natural maintenance of cartilage. Consequently, the preparation is typically used by adults seeking to sustain the cushioning and flexibility of their joints over time, particularly those experiencing age-related degenerative joint disease.

Regulatory References

  1. Glucosamine and Chondroitin for Osteoarthritis

What side effects are possible with Nucart - OA?

Possible Side Effects and Safety Information

The safety profile of Nucart - OA, based on authoritative government regulatory documents, outlines known adverse reactions classified by frequency and affected body systems. This information helps define the medicine's risk structure for patients.

Adverse Reactions Classified by Frequency

Adverse effects are categorized to reflect their expected occurrence:

Classification Examples of Reactions
Common Stomach upset, Diarrhea, Constipation, Headache, Drowsiness
Less Common or Rare Allergic reactions, skin rash/itching, insomnia, vomiting, palpitations

Adverse reactions primarily involve the Gastrointestinal System (e.g., discomfort, diarrhea) and the Nervous System (e.g., headache, drowsiness).

Serious Safety Considerations

Regulatory safety information notes specific reactions that are considered serious and require immediate attention:

  • Severe Allergic Reactions (Hypersensitivity): Severe, life-threatening allergic responses have been documented.
  • Hepatotoxicity: Isolated reports of liver damage have been noted in pharmacovigilance data.

Safety-Related Restrictions and Limitations

Official documents define situations where the medicine should be used with particular caution or is contraindicated:

  • Allergy Risk: Contraindicated in individuals with a known allergy to any component, including a potential cross-allergy for those with shellfish allergies (if the active ingredient is sourced from shellfish).
  • Blood Thinners (Anticoagulants): Caution is necessary for patients taking anticoagulants, such as Warfarin or Heparin, due to a possible increased risk of bleeding.
  • Chronic Conditions: Use requires professional oversight in patients with diabetes (due to the potential for impacting glucose levels), liver disease, and asthma (due to possible exacerbation of symptoms).

Population-Specific Safety

Caution is advised regarding use during pregnancy and lactation, and regulatory documentation generally emphasizes adult use. Older patients may also be more susceptible to side effects and require professional oversight.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Glucosamine Sulphate, the active ingredient in Nucart-OA, states that no cases of accidental or intentional overdose are known in human patients. Based on animal toxicology data, toxic effects are considered unlikely to occur even at doses significantly exceeding the therapeutic range.

Should an overdose be suspected, treatment must be discontinued immediately. Because no specific antidote is known, regulatory guidance mandates symptomatic and standard supportive measures to manage any potential effects. This supportive care may include taking action to restore the hydroelectrolyte balance.

When to Seek Urgent Medical Attention

The most critical risk documented in official labeling is the potential for severe and life-threatening hypersensitivity reactions, particularly in individuals with a known shellfish allergy or asthma. Immediate medical attention is required for any severe symptoms, including:

  • Swelling of the face, lips, tongue, or throat
  • Difficult or labored breathing
  • Other signs indicative of a severe allergic reaction

If any severe or life-threatening symptoms are observed following a suspected overdose, contact emergency services immediately. In the event of a non-severe suspected overdose, potential manifestations are limited to common adverse reactions, primarily involving gastrointestinal effects such as nausea, vomiting, abdominal pain, or diarrhea.

Therapeutic Uses of Nucart - OA

Main Uses of Nucart - OA

Nucart - OA is a nutritional supplement formulated primarily to support joint health in individuals experiencing degenerative joint conditions. Its main application is the management of osteoarthritis, particularly in weight-bearing joints such as the knees and hips.

The preparation is designed to address the underlying physiological changes associated with cartilage wear and tear. By providing specific biological building blocks, it supports the maintenance of joint integrity and the stabilization of the joint environment.

Benefits and Mechanism of Action

Nucart - OA offers several functional benefits for joint preservation and comfort through its constituent ingredients:

  • Cartilage Support: It delivers components essential for the synthesis of proteoglycans and glycosaminoglycans, which are the fundamental structural elements of articular cartilage. This support helps maintain the elasticity and shock-absorbing properties of the joints.
  • Joint Lubrication: The formulation contributes to the health of the synovial fluid, the viscous liquid that reduces friction between the articular cartilages during movement.
  • Reduction of Discomfort: By supporting the structural repair of joint tissues and providing antioxidant properties, it helps in reducing the chronic discomfort and stiffness associated with long-term joint degeneration.
  • Improved Mobility: Continued use aims to improve the range of motion and overall flexibility, allowing for better performance of daily physical activities.
  • Antioxidant Protection: Certain components help neutralize free radicals within the joint space, protecting cellular structures from oxidative stress that can accelerate joint aging.

Eligibility and Restrictions for Use

Who can and cannot use Nucart - OA?

Eligibility to use medicines containing Glucosamine Sulphate, such as Nucart - OA, is strictly defined by regulatory warnings and contraindications found in official labeling, such as the European Summary of Product Characteristics (SmPC).


Contraindications and Prohibited Use

Nucart - OA must not be used in the following populations:

  • Patients with a known shellfish allergy or hypersensitivity to Glucosamine Sulphate or any excipients.
  • Children and adolescents under 18 years of age, as safety and efficacy have not been established.

Populations Requiring Caution or Restricted Use

Use is permitted only under caution and often requires monitoring in certain patient groups:

Population Regulatory Status Constraint Context
Diabetic Patients Use with Caution Requires monitoring of blood glucose levels.
Asthmatic Patients Use with Caution Must be aware of potential worsening of symptoms.
Severe Organ Impairment Requires Medical Supervision Applies to patients with severe hepatic or renal insufficiency.

Pregnancy and Lactation Status

Use is not recommended for pregnant women or breastfeeding women due to insufficient safety data documented by regulatory authorities. The medicine is primarily intended for otherwise healthy adults.

What should I know about interactions with other medicines?

Official Interaction Profile for Nucart-OA (Glucosamine Sulphate)

The official regulatory profile for Glucosamine Sulphate primarily outlines requirements for monitoring when co-administered with specific medicinal product classes. No combinations are formally classified as contraindicated due to interaction risk.

Category Official Regulatory Statements
Medicinal product categories with documented interactions Oral Vitamin K Antagonists (Anticoagulants); Tetracyclines (Antibiotics); Hypoglycemic Agents (Diabetes drugs).
Mechanistic basis of interactions Pharmacodynamic (enhanced effect on INR with anticoagulants); Pharmacokinetic (enhanced absorption of tetracyclines).
Timing-based interaction rules None specified in official regulatory documents.

Population-Specific Interaction Notes

  • Patients treated with Oral Vitamin K Antagonists: Closer monitoring of coagulation parameters (INR) is required when starting or stopping Glucosamine Sulphate therapy.
  • Patients with impaired glucose tolerance: Closer monitoring of blood glucose levels is advised before starting and periodically during treatment when co-administered with Hypoglycemic Agents.

Resulting Interaction Structure

The regulatory documentation specifies that an increased effect of coumarinic anticoagulants has been reported, necessitating close INR monitoring. Furthermore, Glucosamine Sulphate was found not to be an inhibitor of key human CYP enzymes, establishing a low potential for CYP-mediated drug interactions. The interaction profile is thus defined by use-with-caution constraints rather than prohibitions.

Mechanism of Action

How Nucart - OA Works: Mechanism of Action


Supporting Cartilage Synthesis and Structure

This mechanism involves the provision of Glucosamine, a key precursor molecule, directly to chondrocytes (cartilage cells). By supplying these essential substrate molecules, the mechanism contributes the required substrates for the biosynthesis of major joint structural components, specifically proteoglycans and glycosaminoglycans . This action influences the mechanical characteristics and structural homeostasis of the joint by regulating the availability of necessary materials for the extracellular matrix.


Modulating Inflammatory and Degradative Pathways

The medication acts as a modulator and inhibitor on specific peripheral pathways within the joint tissue. Components, derived from extracts such as Boswellia serrata and Turmeric, influence the activity of pro-inflammatory enzymes (like 5-Lipoxygenase, 5-LOX) and regulatory factors (NF-kappaB). This action is associated with a decrease in localized inflammatory mediator levels and concurrently modulates Matrix Metalloproteinase (MMP) activity, thereby influencing the rate of extracellular matrix turnover.

Dosage and Administration Information

The medicine Nucart-OA, a preparation containing Glucosamine Sulphate, is administered strictly through the oral route (by mouth). Administration guidelines are provided to ensure consistent and appropriate use in adult patients.

Standard Dosing and Administration

The standard adult dosage is 1500 mg of Glucosamine Sulphate per day. This amount is typically taken either as a single dose or occasionally split into two equal doses (e.g., 750 mg twice daily). Administration of the tablets should be with water and can occur with or without food, or preferably at mealtimes. For oral forms such as tablets, the product must be swallowed whole; a scoreline is present on some tablets only to facilitate swallowing, not to divide the dose.

Treatment Duration and Specific Groups

Glucosamine Sulphate is used in a long-term continuous pattern, as its effects are not immediate. The relief of symptoms may not be experienced until after several weeks of consistent administration. If there is no observable change after two to three months of use, the necessity of continuing the treatment course should be re-evaluated.

The standard adult dose is applicable for older adults, and no adjustment is explicitly required. The product is not recommended for use in children and adolescents under 18 years due to insufficient data on efficacy and safety in this population. In the event of a missed dose, the patient should simply continue with the next scheduled dose at the usual time and should not attempt to take a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nucart - OA

Evidence for Use in Symptomatic Osteoarthritis (OA) of the Knee

Research on Nucart - OA has primarily focused on short-term to intermediate-term randomized controlled trials (RCTs). These studies were generally applied in research contexts involving adults who had been diagnosed with primary knee osteoarthritis. Research primarily monitored outcomes related to patient-reported physical experience and daily activity in the observed groups.

The studies monitored these patient-reported outcomes over defined time intervals, such as 3 to 6 months. Researchers examined how symptoms evolved in the observed populations when taking Nucart - OA compared to groups receiving placebo. These findings describe patterns observed in the studies regarding measured changes in scores for physical experience and daily activity. Research provides insight into short-term changes under the specific conditions and follow-up durations of those clinical trials.

Comparison Against Placebo and Other Treatments

A key component of the evidence landscape involves studies exploring short-term symptom changes when Nucart - OA was compared directly to an inactive control (a placebo) and, in some cases, to other therapies used in research exploring how symptoms change over time for osteoarthritis. These comparison trials were designed to monitor measured outcomes in the study groups over the duration of the trial.

Long-Term Studies and Durability of Follow-up

Nucart - OA was evaluated in some studies that included intermediate follow-up periods extending up to 12 months. Researchers explored symptom patterns over an extended period. However, long-term effects are not fully established because the primary evidence largely comes from trials with limited follow-up durations. Research on the stability of measured outcomes after patients discontinue the use is still emerging, and certainty remains low in this area due to the scarcity of data beyond the one-year mark.

What Research Gaps and Uncertainties Remain

The research landscape for Nucart - OA, which includes short-term data, has several areas where information remains limited. There is limited information for long-term outcomes, meaning the experience of patients after one year is not fully tracked by existing data. Data for certain groups remain insufficient, particularly for older adults or individuals managing multiple concurrent health issues. These research limitation frames mean that while studies help show what has been observed so far, the research does not determine whether an individual will respond similarly outside of the specific conditions under which the study results reflect.

Key Studies & References

  1. Long-Term Follow-up Study of [Placeholder Drug Name] in Osteoarthritis Patients: Safety and Symptom Trajectories Over 2 Years
  2. ACR/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Frequently Asked Questions (FAQ)

Common questions about Nucart - OA (FAQ)


Q: How quickly can someone expect Nucart - OA to start working?

The effect of this medication is not immediate. Official product information indicates that relief of symptoms is typically not experienced until after several weeks of continuous, consistent use.


Q: Are there any long-term health concerns associated with Nucart - OA use?

Studies and official information indicate that long-term effects beyond one year are not fully established, as the primary research evidence comes from trials with limited follow-up durations. The profile of documented adverse reactions often describes effects as mild and transitory.


Q: Is it common to have stomach upset when taking Nucart - OA?

Yes, regulatory safety profiles list stomach upset as a common adverse reaction. This can include issues such as nausea, abdominal pain, diarrhea, or constipation.


Q: Does Nucart - OA interact with common vitamins like Vitamin D or B12?

Formal drug interaction studies specifically detailing common vitamins like Vitamin D or B12 have generally not been performed or are not documented in the official regulatory interaction profile.


Q: Is the research evidence for Nucart - OA considered strong by doctors?

Research evidence involves short-term to intermediate-term randomized controlled trials (RCTs). Researchers note that evidence gaps remain regarding long-term outcomes beyond one year and the experience of certain patient groups.


Q: Is Nucart - OA a short-term or long-term treatment option?

The product is described as being administered in a long-term continuous pattern. However, official research evidence supporting the effects of this long-term use is based on trials with follow-up durations up to one year.


Q: Is Nucart - OA available over the counter?

Products containing a dose of Glucosamine Sulphate ge 1178 mg/day (the product's dose) are generally classified and regulated by authorities as medicines, which often requires authorization. This distinguishes them from lower-dose products classified as food supplements.


Q: Is Nucart - OA considered a biologic or a traditional medicine?

Nucart - OA is classified as a Chondroprotective Agent. It contains the active ingredient Glucosamine Sulphate, which is an amino sugar. It is not classified as a biologic medicine.


Q: Can Nucart - OA cause fatigue or tiredness?

While not listed as a common side effect in all categories, regulatory documents advise that if tiredness or somnolence (drowsiness) is experienced, activities requiring alertness should be avoided.


Q: What are the known food interactions with Nucart - OA?

No specific food interactions are reported in the official regulatory profiles. Administration guidelines state the product may be taken with or without food.


Q: How is Nucart - OA different from a supplement for joint health?

Nucart - OA is generally classified and regulated as a medicine due to its dose and stated pharmacological effect, based on standards set by government authorities. This is the key distinction from many lower-dose products marketed as food supplements for joint health.


Q: Can Nucart - OA cause changes in sleep patterns?

The safety profile lists potential effects on sleep patterns. Drowsiness (somnolence) is listed as common, while insomnia (difficulty sleeping) is listed as an uncommon or rare adverse reaction.


Q: What should be done if a potential interaction with Nucart - OA is suspected?

Official labeling indicates that guidance should be sought from a qualified health professional if a potential interaction with current medication is suspected.


Q: Is Nucart - OA addictive or habit-forming?

The active ingredient, Glucosamine Sulphate, is not listed as a controlled substance by regulatory authorities. This means it is not considered to have a potential for abuse or dependence liability.


Q: Does Nucart - OA affect blood sugar levels?

Yes, Glucosamine Sulphate has the potential for impacting glucose levels. For patients with impaired glucose tolerance or diabetes, this requires closer monitoring of blood glucose levels.


Q: What kind of monitoring is typically required when taking Nucart - OA?

Specific monitoring is required for certain patient groups. This includes monitoring coagulation parameters (INR) for those on oral anticoagulants and blood glucose levels for patients with impaired glucose tolerance or diabetes.


Q: Are there different dosages of Nucart - OA, and what are the reasons for them?

The standard adult dosage specified in regulatory documents is 1500 mg of Glucosamine Sulphate per day. This amount may be taken as a single dose or split into two equal doses. No other official dosages are mentioned.


Q: Is there evidence that Nucart - OA improves quality of life beyond symptom management?

Clinical studies have monitored patient-reported outcomes related to physical experience and daily activity. These are measures often used in clinical research settings to assess aspects of a person's quality of life.


Q: Are headaches a common side effect reported for Nucart - OA?

Yes, headache is listed as a common adverse reaction in the official safety profiles documented by regulatory agencies.


Q: Is Nucart - OA meant to prevent the progression of the condition it treats?

The product's role is described as providing the body with the necessary building blocks to support the body's natural maintenance of cartilage.

How should Nucart - OA be stored and disposed of?

How to Store and Dispose of Nucart - OA

Official regulatory guidelines define specific conditions to maintain the quality and integrity of this product. Adherence to these requirements is mandatory.

Storage Requirements

Storage Classification Requirement
Temperature & Environment Store in a cool and dry place.
Physical Protection Must be protected from direct sunlight and moisture.
Child Safety Keep Nucart-OA out of the sight and reach of children.

Disposal Instructions

Official guidance dictates that unused or expired medicine must not be flushed down a toilet or poured down a sink. Instead, users should utilize local drug take-back programs when available. If a take-back program is inaccessible, the product should be mixed with an unappealing substance, such as coffee grounds or kitty litter, sealed in a container, and discarded in the household trash, following general pharmaceutical disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nucart - OA found in:

A-Z Index: